VBL Therapeutics announces second successful pre-planned interim analysis with a positive data safety monitoring committee review looking at OS - the primary endpoint of the OVAL Phase III potential registration study of VB 111 in Ovarian Cancer.
Why sign up with Medthority?
Develop your knowledge with our disease and condition focused Learning Zones
Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines
Personalised dashboard providing updates and recommendations for content within your areas of interest